• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用电子临床数据追踪 SARS-CoV-2 相关脓毒症的发病率和死亡率。

Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2-Associated Sepsis.

机构信息

Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, Massachusetts.

Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

出版信息

JAMA Netw Open. 2023 Sep 5;6(9):e2335728. doi: 10.1001/jamanetworkopen.2023.35728.

DOI:10.1001/jamanetworkopen.2023.35728
PMID:37773495
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10543118/
Abstract

IMPORTANCE

Efforts to quantify the burden of SARS-CoV-2-associated sepsis have been limited by inconsistent definitions and underrecognition of viral sepsis.

OBJECTIVE

To describe the incidence and outcomes of SARS-CoV-2-associated sepsis vs presumed bacterial sepsis using objective electronic clinical criteria.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included adults hospitalized at 5 Massachusetts hospitals between March 2020 and November 2022.

EXPOSURES

SARS-CoV-2-associated sepsis was defined as a positive SARS-CoV-2 polymerase chain reaction test and concurrent organ dysfunction (ie, oxygen support above simple nasal cannula, vasopressors, elevated lactate level, rise in creatine or bilirubin level, and/or decline in platelets). Presumed bacterial sepsis was defined by modified US Centers for Disease Control and Prevention adult sepsis event criteria (ie, blood culture order, sustained treatment with antibiotics, and organ dysfunction using identical thresholds as for SARS-CoV-2-associated sepsis).

MAIN OUTCOMES AND MEASURES

Trends in the quarterly incidence (ie, proportion of hospitalizations) and in-hospital mortality for SARS-CoV-2-associated and presumed bacterial sepsis were assessed using negative binomial and logistic regression models.

RESULTS

This study included 431 017 hospital encounters from 261 595 individuals (mean [SD] age 57.9 [19.8] years, 241 131 (55.9%) females, 286 397 [66.5%] from academic hospital site). Of these encounters, 23 276 (5.4%) were from SARS-CoV-2, 6558 (1.5%) had SARS-CoV-2-associated sepsis, and 30 604 patients (7.1%) had presumed bacterial sepsis without SARS-CoV-2 infection. Crude in-hospital mortality for SARS-CoV-2-associated sepsis declined from 490 of 1469 (33.4%) in the first quarter to 67 of 450 (14.9%) in the last (adjusted odds ratio [aOR], 0.88 [95% CI, 0.85-0.90] per quarter). Crude mortality for presumed bacterial sepsis was 4451 of 30 604 patients (14.5%) and stable across quarters (aOR, 1.00 [95% CI, 0.99-1.01]). Medical record reviews of 200 SARS-CoV-2-positive hospitalizations confirmed electronic health record (EHR)-based SARS-CoV-2-associated sepsis criteria performed well relative to sepsis-3 criteria (90.6% [95% CI, 80.7%-96.5%] sensitivity; 91.2% [95% CI, 85.1%-95.4%] specificity).

CONCLUSIONS AND RELEVANCE

In this retrospective cohort study of hospitalized adults, SARS-CoV-2 accounted for approximately 1 in 6 cases of sepsis during the first 33 months of the COVID-19 pandemic. In-hospital mortality rates for SARS-CoV-2-associated sepsis were high but declined over time and ultimately were similar to presumed bacterial sepsis. These findings highlight the high burden of SARS-CoV-2-associated sepsis and demonstrate the utility of EHR-based algorithms to conduct surveillance for viral and bacterial sepsis.

摘要

重要性

由于 SARS-CoV-2 相关脓毒症的定义不一致以及对病毒性脓毒症的认识不足,因此对其负担进行量化的努力受到了限制。

目的

使用客观的电子临床标准描述 SARS-CoV-2 相关脓毒症与推定细菌性脓毒症的发生率和结局。

设计、地点和参与者:这项回顾性队列研究纳入了 2020 年 3 月至 2022 年 11 月期间在马萨诸塞州的 5 家医院住院的成年人。

暴露

SARS-CoV-2 相关脓毒症的定义是 SARS-CoV-2 聚合酶链反应检测呈阳性和同时出现器官功能障碍(即需要高于简单鼻导管的氧气支持、血管加压药、升高的乳酸水平、肌酐或胆红素水平升高和/或血小板减少)。推定细菌性脓毒症的定义是根据美国疾病控制与预防中心的成人脓毒症事件标准进行修改的(即血培养订单、持续使用抗生素治疗以及使用与 SARS-CoV-2 相关脓毒症相同的阈值进行的器官功能障碍)。

主要结果和措施

使用负二项式和逻辑回归模型评估 SARS-CoV-2 相关和推定细菌性脓毒症在每季度(即住院比例)的发生率和院内死亡率趋势。

结果

这项研究包括了 261595 名个体的 431017 次住院治疗(平均[标准差]年龄为 57.9[19.8]岁,241131 名[55.9%]女性,286397 名[66.5%]来自学术医院)。在这些住院治疗中,有 23276 例(5.4%)是 SARS-CoV-2 感染,6558 例(1.5%)为 SARS-CoV-2 相关脓毒症,30604 例(7.1%)为没有 SARS-CoV-2 感染的推定细菌性脓毒症。SARS-CoV-2 相关脓毒症的院内死亡率从第 1 季度的 1469 例中的 490 例(33.4%)下降到最后一个季度的 450 例中的 67 例(调整后的优势比[OR],每季度 0.88[95%CI,0.85-0.90])。推定细菌性脓毒症的死亡率为 30604 例患者中的 4451 例(14.5%),且在各季度之间保持稳定(OR,1.00[95%CI,0.99-1.01])。对 200 例 SARS-CoV-2 阳性住院患者的病历审查证实,基于电子健康记录(EHR)的 SARS-CoV-2 相关脓毒症标准与脓毒症-3 标准相比表现良好(敏感性 90.6%[95%CI,80.7%-96.5%];特异性 91.2%[95%CI,85.1%-95.4%])。

结论和相关性

在这项 COVID-19 大流行的前 33 个月期间,对住院成年人的回顾性队列研究中,SARS-CoV-2 约占脓毒症病例的 1/6。SARS-CoV-2 相关脓毒症的院内死亡率很高,但随着时间的推移而下降,最终与推定细菌性脓毒症相似。这些发现强调了 SARS-CoV-2 相关脓毒症的高负担,并证明了基于 EHR 的算法在监测病毒性和细菌性脓毒症方面的实用性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10543118/9b99c81300dd/jamanetwopen-e2335728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10543118/63827e88be82/jamanetwopen-e2335728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10543118/9b99c81300dd/jamanetwopen-e2335728-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10543118/63827e88be82/jamanetwopen-e2335728-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fed/10543118/9b99c81300dd/jamanetwopen-e2335728-g002.jpg

相似文献

1
Use of Electronic Clinical Data to Track Incidence and Mortality for SARS-CoV-2-Associated Sepsis.利用电子临床数据追踪 SARS-CoV-2 相关脓毒症的发病率和死亡率。
JAMA Netw Open. 2023 Sep 5;6(9):e2335728. doi: 10.1001/jamanetworkopen.2023.35728.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效:一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014.2009 - 2014年美国医院中使用临床数据与索赔数据的脓毒症发病率及趋势
JAMA. 2017 Oct 3;318(13):1241-1249. doi: 10.1001/jama.2017.13836.
4
Outcomes Among Patients Hospitalized With Non-COVID-19 Conditions Before and During the COVID-19 Pandemic in Alberta and Ontario, Canada.在加拿大艾伯塔省和安大略省,与 COVID-19 无关的疾病住院患者在 COVID-19 大流行前后的结果。
JAMA Netw Open. 2023 Jul 3;6(7):e2323035. doi: 10.1001/jamanetworkopen.2023.23035.
5
Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative.利用美国国家 COVID 队列协作的数据,对美国成年人中 SARS-CoV-2 感染的临床特征和临床严重程度进行临床描述和预测。
JAMA Netw Open. 2021 Jul 1;4(7):e2116901. doi: 10.1001/jamanetworkopen.2021.16901.
6
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
7
Variation in Identifying Sepsis and Organ Dysfunction Using Administrative Versus Electronic Clinical Data and Impact on Hospital Outcome Comparisons.使用行政数据与电子临床数据识别脓毒症和器官功能障碍的差异及其对医院预后比较的影响。
Crit Care Med. 2019 Apr;47(4):493-500. doi: 10.1097/CCM.0000000000003554.
8
Assessment of Hospital-Onset SARS-CoV-2 Infection Rates and Testing Practices in the US, 2020-2022.2020-2022 年美国医院获得性 SARS-CoV-2 感染率和检测实践评估。
JAMA Netw Open. 2023 Aug 1;6(8):e2329441. doi: 10.1001/jamanetworkopen.2023.29441.
9
Factors Associated With Severe COVID-19 Among Vaccinated Adults Treated in US Veterans Affairs Hospitals.与接受美国退伍军人事务部医院治疗的已接种疫苗成年人中 COVID-19 重症相关的因素。
JAMA Netw Open. 2022 Oct 3;5(10):e2240037. doi: 10.1001/jamanetworkopen.2022.40037.
10
Trends in antibiotic utilization for patients hospitalized with COVID-19 with and without signs of sepsis.新型冠状病毒肺炎住院患者(有或无脓毒症体征)抗生素使用趋势。
Antimicrob Steward Healthc Epidemiol. 2024 Oct 3;4(1):e143. doi: 10.1017/ash.2024.366. eCollection 2024.

引用本文的文献

1
Immune Signatures Distinguish Pure and Mixed Sepsis in Critical COVID-19: A Retrospective Cohort Study.免疫特征区分重症COVID-19中的单纯性和混合性脓毒症:一项回顾性队列研究
J Inflamm Res. 2025 Aug 14;18:11139-11153. doi: 10.2147/JIR.S531962. eCollection 2025.
2
Impact of COVID-19 on disease-specific mortality, healthcare resource utilization, and disease burden across a population over 1 billion in 31 countries: an interrupted time-series analysis.2019年冠状病毒病对31个国家10亿多人口的特定疾病死亡率、医疗资源利用及疾病负担的影响:一项中断时间序列分析
EClinicalMedicine. 2025 Jul 5;85:103315. doi: 10.1016/j.eclinm.2025.103315. eCollection 2025 Jul.
3

本文引用的文献

1
Impact of changing case definitions for coronavirus disease 2019 (COVID-19) hospitalization on pandemic metrics.改变 2019 冠状病毒病(COVID-19)住院病例定义对大流行指标的影响。
Infect Control Hosp Epidemiol. 2023 Sep;44(9):1458-1466. doi: 10.1017/ice.2022.300. Epub 2023 Mar 13.
2
Mortality Rates by Age Group and Intubation Status in Hospitalized Adult Patients From 21 United States Hospital Systems During Three Surges of the COVID-19 Pandemic.21个美国医院系统中住院成年患者在新冠疫情三次高峰期间按年龄组和插管状态划分的死亡率
Chest. 2023 Jun;163(6):1390-1394. doi: 10.1016/j.chest.2023.01.029. Epub 2023 Jan 30.
3
Poor clinical outcomes in respiratory viral sepsis: a retrospective observational study.
呼吸道病毒性脓毒症的不良临床结局:一项回顾性观察研究。
ERJ Open Res. 2025 Jun 2;11(3). doi: 10.1183/23120541.00836-2024. eCollection 2025 May.
4
Mitigating Bias in Machine Learning Models with Ethics-Based Initiatives: The Case of Sepsis.通过基于伦理的举措减轻机器学习模型中的偏差:脓毒症案例
Am J Bioeth. 2025 May 12:1-14. doi: 10.1080/15265161.2025.2497971.
5
Impacts of the COVID-19 pandemic on sepsis incidence, etiology and hospitalization costs in France: a retrospective observational study.新冠疫情对法国脓毒症发病率、病因及住院费用的影响:一项回顾性观察研究
BMC Infect Dis. 2025 Apr 29;25(1):627. doi: 10.1186/s12879-025-11000-7.
6
Viral sepsis: diagnosis, clinical features, pathogenesis, and clinical considerations.病毒性脓毒症:诊断、临床特征、发病机制及临床考量
Mil Med Res. 2024 Dec 16;11(1):78. doi: 10.1186/s40779-024-00581-0.
7
Association Between the Sequence of β-Lactam and Vancomycin Administration and Mortality in Patients With Suspected Sepsis.β-内酰胺类药物与万古霉素给药顺序与疑似脓毒症患者死亡率之间的关联
Clin Infect Dis. 2025 Apr 30;80(4):761-769. doi: 10.1093/cid/ciae599.
8
An optimal antibiotic selection framework for Sepsis patients using Artificial Intelligence.一种使用人工智能的脓毒症患者最佳抗生素选择框架。
NPJ Digit Med. 2024 Nov 29;7(1):343. doi: 10.1038/s41746-024-01350-y.
9
Circulating extracellular vesicles from severe COVID-19 patients induce lung inflammation.严重 COVID-19 患者的循环细胞外囊泡诱导肺部炎症。
mSphere. 2024 Nov 21;9(11):e0076424. doi: 10.1128/msphere.00764-24. Epub 2024 Oct 30.
10
Cholesterol and Cholesterol-Lowering Medications in COVID-19-An Unresolved Matter.胆固醇和降胆固醇药物在 COVID-19 中的作用——一个悬而未决的问题。
Int J Mol Sci. 2024 Sep 29;25(19):10489. doi: 10.3390/ijms251910489.
COVID-19 bacteremic co-infection is a major risk factor for mortality, ICU admission, and mechanical ventilation.
COVID-19 菌血症合并感染是导致死亡率、重症监护病房(ICU)入院率和机械通气率增加的主要危险因素。
Crit Care. 2023 Jan 23;27(1):34. doi: 10.1186/s13054-023-04312-0.
4
Meeting the Challenges of Sepsis in Severe Coronavirus Disease 2019: A Call to Arms.应对2019年重症冠状病毒病中的脓毒症挑战:战斗的号角
Open Forum Infect Dis. 2022 Dec 1;10(1):ofac645. doi: 10.1093/ofid/ofac645. eCollection 2023 Jan.
5
Update on Sepsis Epidemiology in the Era of COVID-19.新冠疫情时代脓毒症的流行病学研究进展
Semin Respir Crit Care Med. 2023 Feb;44(1):173-184. doi: 10.1055/s-0042-1759880. Epub 2023 Jan 16.
6
Bacterial co-infection and antibiotic stewardship in patients with COVID-19: a systematic review and meta-analysis.COVID-19 患者的细菌合并感染和抗生素管理:系统评价和荟萃分析。
BMC Infect Dis. 2023 Jan 9;23(1):14. doi: 10.1186/s12879-022-07942-x.
7
Gender and Race-Based Health Disparities in COVID-19 Outcomes among Hospitalized Patients in the United States: A Retrospective Analysis of a National Sample.美国住院患者中 COVID-19 结局的性别和种族健康差异:一项全国样本的回顾性分析
Vaccines (Basel). 2022 Nov 29;10(12):2036. doi: 10.3390/vaccines10122036.
8
Integrated host-microbe plasma metagenomics for sepsis diagnosis in a prospective cohort of critically ill adults.整合宿主-微生物血浆宏基因组学用于危重症成年患者脓毒症的前瞻性队列诊断。
Nat Microbiol. 2022 Nov;7(11):1805-1816. doi: 10.1038/s41564-022-01237-2. Epub 2022 Oct 20.
9
Mortality Risk Among Patients Hospitalized Primarily for COVID-19 During the Omicron and Delta Variant Pandemic Periods - United States, April 2020-June 2022.在奥密克戎和德尔塔变异株流行期间因 COVID-19 住院的患者的死亡率风险 - 美国,2020 年 4 月-2022 年 6 月。
MMWR Morb Mortal Wkly Rep. 2022 Sep 16;71(37):1182-1189. doi: 10.15585/mmwr.mm7137a4.
10
Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set.COVID-19 重症监护病房患者的合并感染和 ICU 获得性感染:对 UNITE-COVID 数据集的二次分析。
Crit Care. 2022 Aug 3;26(1):236. doi: 10.1186/s13054-022-04108-8.